Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis: a Novel, Advanced Multimodal MRI and Optical Coherence Tomography-Angiography (OCTA) Study
The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and optical coherence tomography angiography (OCT-A)..
• Patients who have chosen to start ocrelizumab and for whom ocrelizumab is determined to be the most appropriate standard-of-care disease modifying therapy (DMT) by the treating neurologist.
• May be treatment naive, or had suboptimal response to no more than one DMT after an adequate course of treatment (defined as treatment duration of 6+ months).
• Age 18 to 60 years old.
• Ethnicity: self-identified as African American or Caucasian.
• Clinically definite relapsing remitting multiple sclerosis (RRMS) per 2017 revised McDonald criteria.
• EDSS from 0 to 6 (inclusive) at baseline visit.
• Able to give informed consent.
• Able to have MRI scans.